2007
320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras
Radojcic V, Skarica M, Murphy G, Luznik L. 320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras. Transplantation And Cellular Therapy 2007, 13: 116-117. DOI: 10.1016/j.bbmt.2006.12.325.Peer-Reviewed Original ResearchFactors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Durakovic N, Radojcic V, Skarica M, Bezak K, Powell J, Fuchs E, Luznik L. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood 2007, 109: 4564-4574. PMID: 17227829, PMCID: PMC1885486, DOI: 10.1182/blood-2006-09-048124.Peer-Reviewed Original ResearchConceptsDonor lymphocyte infusionDonor T cellsHost T cellsBone marrow transplantationT cellsHost chimerismHost APCsMarrow transplantationPrevious sensitizationAllogeneic bone marrow transplantationToll-like receptor ligandsGvH responseGVL reactivityLeukemia reactivityLymphocyte infusionMixed chimerismTLR ligandsHost antigensMurine modelVivo administrationCell activatorsHigh levelsAlloreactivityChimerismMHC
2005
After MHC-matched allografting, host-derived langerhans cells (LCs) persist in skin and cutaneous lymph nodes in the steady-state and are the targets of DLI-mediated alloresponse
Durakovic N, Bezak K, Skarica M, Fuchs E, Luznik L. After MHC-matched allografting, host-derived langerhans cells (LCs) persist in skin and cutaneous lymph nodes in the steady-state and are the targets of DLI-mediated alloresponse. Transplantation And Cellular Therapy 2005, 11: 12. DOI: 10.1016/j.bbmt.2004.12.033.Peer-Reviewed Original Research